Impact BioMedical Inc. (IBO) has completed a business combination with Zoar Limited (formerly Dr Ashleys Limited). The transaction, finalized on November 17, 2026, resulted in the Company changing its name to Dr Ashleys USA Inc. and delisting its common stock from the NYSE American.
Under the terms of the Merger Agreement, Merger Sub merged with and into Impact BioMedical, with the Company continuing as the surviving corporation. As a result, Impact BioMedical shareholders received PubCo Ordinary Shares. Following a 1-for-12.62 reverse stock split, holders of the Company's common stock received a total of 8,640,000 PubCo Ordinary Shares, representing approximately 4.80% of the total issued shares at closing.
The PubCo Ordinary Shares issued in the transaction were registered under a Form F-4 Registration Statement declared effective by the SEC on October 23, 2026. The shares are expected to begin trading on the NYSE American under the symbol "ZOAR" on November 18, 2026.
Prior to the closing, the Company’s board of directors, Chief Financial Officer, and Chief Operating Officer resigned. The new board of directors for PubCo, the Company’s parent, includes Kanans Visvanats (Chairman), Donald Kalkofen, Michael Zajas, Evan Lim, Neha Kumari, Maduabuchi Nelson Okey, Bang-Ning (Simon) Liu, and David A. Sanders.
PubCo issued a total of 167,976,000 PubCo Ordinary Shares to Kanans Visvanats, the sole shareholder of Zoar, representing approximately 94.02% of the total issued shares. Additionally, PubCo issued 22,000 shares to Impact BioMedical’s Chief Executive Officer, Frank D. Heuszel, and 228,000 shares to DSS, Inc.
Following the closing, the Company notified NYSE American to suspend trading of its common stock prior to November 18, 2026, and filed a Form 25 to delist the stock. The Company also intends to file a Form 15 to deregister its securities and suspend its reporting obligations under the Exchange Act.